4 FDA drug decisions on the horizon

03/18/2013 | Investor's Business Daily

The FDA is poised to decide on Biogen Idec's multiple sclerosis drug BG-12 by March 28, while United Therapeutics is set to receive a verdict by March 31 for the lung drug Remodulin. Johnson & Johnson's diabetes drug Invokana and Map Pharmaceuticals' migraine drug Levadex are also set to receive federal decisions by March 31 and April 15, respectively.

View Full Article in:

Investor's Business Daily

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC